Biomarkers are central to modern drug development. As an end to end global CRO, Cliantha provides biomarker testing solutions that help sponsors generate high quality, interpretable data from discovery through late phase trials and post marketing programs.

Comprehensive Biomarker Solutions

Cliantha supports biomarker strategies across therapeutic areas and study phases, including:

• Exploratory biomarkers for hypothesis generation and early clinical insights
• Pharmacodynamic (PD) biomarkers to demonstrate target engagement and biological activity
• Predictive and prognostic biomarkers to inform patient selection and trial enrichment
• Safety biomarkers to support risk monitoring and benefit–risk evaluations
• Translational biomarkers bridging preclinical findings to clinical outcomes